About: Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past
Creator	Gianni, Panagiota Giannis, Dimitrios Ziogas, Ioannis
source	Elsevier; Medline; PMC
abstract	Coronavirus disease 2019 (COVID-19) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus strain disease, has recently emerged in China and rapidly spread worldwide. This novel strain is highly transmittable and severe disease has been reported in up to 16% of hospitalized cases. More than 600,000 cases have been confirmed and the number of deaths is constantly increasing. COVID-19 hospitalized patients, especially those suffering from severe respiratory or systemic manifestations, fall under the spectrum of the acutely ill medical population, which is at increased venous thromboembolism risk. Thrombotic complications seem to emerge as an important issue in patients infected with COVID-19. Preliminary reports on COVID-19 patients’ clinical and laboratory findings include thrombocytopenia, elevated D-dimer, prolonged prothrombin time, and disseminated intravascular coagulation. As the pandemic is spreading and the whole picture is yet unknown, we highlight the importance of coagulation disorders in COVID-19 infected patients and review relevant data of previous coronavirus epidemics caused by the severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and the Middle East Respiratory Syndrome coronavirus (MERS-CoV).
has issue date	2020-04-09(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2020.104362
bibo:pmid	32305883
has license	no-cc
sha1sum (hex)	8a8fadf4e22ceae56d3156e82f817012a9bded95
schema:url	https://doi.org/10.1016/j.jcv.2020.104362
resource representing a document's title	Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past
has PubMed Central identifier	PMC7195278
has PubMed identifier	32305883
schema:publication	J Clin Virol
resource representing a document's body	covid:8a8fadf4e22ceae56d3156e82f817012a9bded95#body_text
is schema:about of	named entity 'Coagulation' named entity 'autopsies' named entity 'infectious agents' named entity 'platelet count' named entity 'epidemic' named entity 'D-dimer' named entity 'D-dimer' named entity 'lung' named entity 'Guangdong' named entity 'cough' named entity 'lung' named entity 'Wuhan' named entity 'procoagulant' named entity 'prothrombotic' named entity 'pathogenetic' named entity 'MERS-CoV' named entity 'upregulation' named entity 'hematologic' named entity 'ventricular tachycardia' named entity 'infection' named entity 'protein' named entity 'SARS-CoV-1' named entity 'white blood cells' named entity 'DIC' named entity 'postmortem' named entity 'platelets' named entity 'tissue factor pathway inhibitor' named entity 'SARS' named entity 'procoagulant' named entity 'MERS-CoV' named entity 'infection' named entity 'fetal' named entity 'nucleocapsid protein' named entity 'platelet count' named entity 'EGR1' named entity 'Platelets' named entity 'autopsy' named entity 'SARS-CoV-1' named entity 'thromboxane' named entity 'myalgia' named entity 'SARS-CoV-2' named entity 'potential treatments' named entity 'autopsies' named entity 'SARS' named entity 'lupus anticoagulant' named entity 'D-dimer' named entity 'lung' named entity 'TLR9' named entity 'thrombocytopenia' named entity 'thrombin' named entity 'animal models' named entity 'MERS-CoV' named entity 'COVID' named entity 'PLSCR1' named entity 'recombinant' named entity 'epidemics' named entity '95% CI' named entity 'Histopathologic examination' named entity 'PAI1' named entity 'coagulation cascade' named entity 'virus' named entity 'fatigue' named entity 'SARS-CoV-1' named entity 'procoagulant' named entity 'PAI1' named entity 'VIIa' named entity 'degranulation' named entity 'clot formation' named entity 'platelet activation' named entity 'D-dimer' named entity 'platelet count' named entity 'COVID' named entity 'prothrombin time' named entity 'fibrotic' named entity 'receptor' named entity 'SARS-CoV-1' named entity 'gene' named entity 'gene' named entity 'thrombosis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software